294 related articles for article (PubMed ID: 34925584)
1. UPDATES IN ENDOCRINE IMMUNE-RELATED ADVERSE EVENTS IN ONCOLOGY IMMUNOTHERAPY.
Coniac S; Stoian M
Acta Endocrinol (Buchar); 2021; 17(2):286-289. PubMed ID: 34925584
[TBL] [Abstract][Full Text] [Related]
2. Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.
Stelmachowska-Banaś M; Czajka-Oraniec I
Endocr Connect; 2020 Oct; 9(10):R207-R228. PubMed ID: 33064663
[TBL] [Abstract][Full Text] [Related]
3. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
4. How we treat endocrine complications of immune checkpoint inhibitors.
Paschou SA; Stefanaki K; Psaltopoulou T; Liontos M; Koutsoukos K; Zagouri F; Lambrinoudaki I; Dimopoulos MA
ESMO Open; 2021 Feb; 6(1):100011. PubMed ID: 33399077
[TBL] [Abstract][Full Text] [Related]
5. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
6. Challenges and Limitations of Endocrine Toxicity Evaluation in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy-Retrospective Study from a Tertiary-Level Hospital in Romania.
Coniac S; Costache Outas MC; Pirvu EE; Patru RI; Gainariu E; Aldea C; Iorga PG; Ambroci M; Liscu HD; Miron AI; Badiu C
Diagnostics (Basel); 2023 May; 13(10):. PubMed ID: 37238273
[TBL] [Abstract][Full Text] [Related]
7. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
8. Monitoring Endocrine Complications of Immunotherapy: A Screening Tool.
Majety P; Groysman A; Seery V; Shea M; Hou R
Cureus; 2022 Jul; 14(7):e26859. PubMed ID: 35974849
[TBL] [Abstract][Full Text] [Related]
9. Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.
Del Rivero J; Cordes LM; Klubo-Gwiezdzinska J; Madan RA; Nieman LK; Gulley JL
Oncologist; 2020 Apr; 25(4):290-300. PubMed ID: 32297436
[TBL] [Abstract][Full Text] [Related]
10. Clinical heterogeneity of hypophysitis secondary to PD-1/PD-L1 blockade: insights from four cases.
Lupi I; Brancatella A; Cosottini M; Viola N; Lanzolla G; Sgrò D; Dalmazi GD; Latrofa F; Caturegli P; Marcocci C
Endocrinol Diabetes Metab Case Rep; 2019 Oct; 2019():. PubMed ID: 31610523
[TBL] [Abstract][Full Text] [Related]
11. American Association of Clinical Endocrinology Disease State Clinical Review: Evaluation and Management of Immune Checkpoint Inhibitor-Mediated Endocrinopathies: A Practical Case-Based Clinical Approach.
Yuen KCJ; Samson SL; Bancos I; Gosmanov AR; Jasim S; Fecher LA; Weber JS
Endocr Pract; 2022 Jul; 28(7):719-731. PubMed ID: 35477029
[TBL] [Abstract][Full Text] [Related]
12. Endocrine side effects of cancer immunotherapy.
Cukier P; Santini FC; Scaranti M; Hoff AO
Endocr Relat Cancer; 2017 Dec; 24(12):T331-T347. PubMed ID: 29025857
[TBL] [Abstract][Full Text] [Related]
13. Management of Endocrine and Metabolic Toxicities of Immune-Checkpoint Inhibitors: From Clinical Studies to a Real-Life Scenario.
Spagnolo CC; Giuffrida G; Cannavò S; Franchina T; Silvestris N; Ruggeri RM; Santarpia M
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612243
[TBL] [Abstract][Full Text] [Related]
14. [Endocrinopathies Associated with Immune Checkpoint Inhibitors].
Santos MJ
Acta Med Port; 2022 Mar; 35(3):209-215. PubMed ID: 35077347
[TBL] [Abstract][Full Text] [Related]
15. Mapping endocrine toxicity spectrum of immune checkpoint inhibitors: a disproportionality analysis using the WHO adverse drug reaction database, VigiBase.
Bai X; Lin X; Zheng K; Chen X; Wu X; Huang Y; Zhuang Y
Endocrine; 2020 Sep; 69(3):670-681. PubMed ID: 32507965
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society.
Kwon H; Roh E; Ahn CH; Kim HK; Ku CR; Jung KY; Lee JH; Kim EH; Suh S; Hong S; Ha J; Moon JS; Kim JH; Kim MK;
Endocrinol Metab (Seoul); 2022 Dec; 37(6):839-850. PubMed ID: 36604955
[TBL] [Abstract][Full Text] [Related]
17. Pituitary and adrenal disorders induced by immune checkpoint inhibitors.
Albarel F; Brue T; Castinetti F
Ann Endocrinol (Paris); 2023 May; 84(3):339-345. PubMed ID: 36965852
[TBL] [Abstract][Full Text] [Related]
18. Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.
Deligiorgi MV; Panayiotidis MI; Trafalis DT
Immunotherapy; 2020 May; 12(7):481-510. PubMed ID: 32345074
[TBL] [Abstract][Full Text] [Related]
19. Incidence of endocrine-related immune-related adverse events in Japanese subjects with various types of cancer.
Iwamoto Y; Kimura T; Iwamoto H; Sanada J; Fushimi Y; Katakura Y; Tatsumi F; Shimoda M; Nakanishi S; Mune T; Kaku K; Kaneto H
Front Endocrinol (Lausanne); 2023; 14():1079074. PubMed ID: 36755909
[TBL] [Abstract][Full Text] [Related]
20. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
